383930.KQ DT&CRO Co. Ltd.

Healthcare Biotechnology KOSDAQ
1,836 KRW
Close of Oct 30, 2026
1,430 4,115
Market cap
KRW 23.5B
P/E
-
P/B
3.26x
ROE
-496.1%
Dividend yield
-
Fundamental score
0.4/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 383930.KQ undervalued?

Graham number

The Graham number of DT&CRO Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DT&CRO Co. Ltd. fundamental analysis

2 of 21 checks passed

ROE 0/2

Low return on equity (-496.1%), below 10%.

ROA 0/1

Return on assets (-39.6%) is below the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-38.8%) is below the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 2.8% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (157.4%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 0/2

Cash covers 0.2 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (3.3x) is above the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

DT&CRO Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DT&CRO Co. Ltd.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.

Full company profile